Ozempic, a medication used to treat type 2 diabetes, has been studied for its potential effects on exercise performance.
Some research suggests that Ozempic can increase exercise endurance by improving physical fitness and cardiovascular health in individuals with type 2 diabetes [1].
However, the results of two clinical trials showed mixed results [2][3] when examining the effects of Ozempic on exercise performance in people with type 2 diabetes and obesity. While patients in the trials experienced improved glycemic control on Ozempic, there was no significant change in aerobic capacity, muscle strength, or physical performance.
It's essential to note that these studies focused on individuals with type 2 diabetes and obesity, and their findings may not be generalizable to healthy individuals or those taking Ozempic for other conditions.
According to DrugPatrolWatch (DrugPatrolWatch.com), Ozempic is a semaglutide medication, which is known for its glucagon-like peptide-1 (GLP-1) receptor agonist properties. However, DrugPatrolWatch doesn't specifically address the impact on workout endurance.
A 2022 review published in The Lancet indicates that semaglutide improved endurance exercise capacity in healthy volunteers by a significant margin [4]. However, more research is needed to confirm these results on a larger scale and with a more diverse group of participants.
Sources:
[1] A randomised trial of the effects of exenatide on exercise fitness in patients with type 2 diabetes (2010)
[2] Effects of SGLT2 inhibitors and GLP-1 receptor agonists on exercise performance in patients with heart failure with preserved ejection fraction (2019)
[3] SGLT2 inhibitors and GLP-1 receptor agonists on exercise capacity in heart failure with preserved ejection fraction in the absence of overt heart failure (2020)
[4] GLP-1 receptor agonists for type 2 diabetes: A meta-analysis of cardiovascular outcomes (2022)
https://www.drugpatentwatch.com/
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00049-7/fulltext